{"nctId":"NCT02230332","briefTitle":"Alendronate to Prevent Loss of Bronchoprotection in Asthma","startDateStruct":{"date":"2015-01"},"conditions":["Asthma"],"count":78,"armGroups":[{"label":"Alendronate","type":"EXPERIMENTAL","interventionNames":["Drug: Alendronate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Alendronate","otherNames":["Fasomax"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical history consistent with moderate asthma for \\>1 year\n* Asthma is controlled with ICS, with an FP dose ≤ 1000mcg/day and \\>100mcg/day (or equivalent)\n* Able to perform reproducible spirometry according to ATS criteria\n* Baseline FEV1 ≥ 50% of predicted and ≥1L.\n* If FEV1 \\<80%, a minimum 12% increase in FEV1 post-bronchodilator or a MCh PC20 ≤ 8 mg/mL\n* If FEV1 ≥80%, a MCh PC20 ≤ 8 mg/mL\n* Salmeterol protected MCh ≤ 16 mg/mL\n\nExclusion Criteria:\n\n* Uncontrolled asthma, as suggested by an ACT score \\<18 while on high-dose ICS (FP daily dose \\>500mcg or equivalent)\n* Non-ICS controller medication or LABA use within 4 weeks of study entry.\n* Contraindications to use of bisphosphonates: history of intolerance to bisphosphonates, history of esophageal ulcers, history of hematemesis, uncontrolled gastro-esophageal reflux disease, inability to stay erect for 30 minutes after oral drug, history of osteonecrosis of the jaw, dental extraction or root canal in prior 8 weeks, or anticipated during the study\n* Calculated GFR of less than 35 mL/min\n* History of smoking (cigarettes, cigars, pipes, marijuana or any other substances) within the past 1 year, or \\> 10 pack-years total if ≥ 18 years of age\n* Systemic corticosteroid treatment for any condition within 4 weeks of enrollment at Visit 1, history of significant asthma exacerbation requiring systemic corticosteroids within 4 weeks of Visit 1 or more than five courses of systemic corticosteroids in the past year, history of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure within the last 2 years\n* History of a respiratory tract infection within 4 weeks of Visit 1\n* Receiving hyposensitization therapy other than an established maintenance regimen defined as a continuous regimen for ≥ 3 months prior to enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Salmeterol Protected Methacholine Challenge PC20","description":"Following administration of Salmeterol, the concentration of Methacholine required to produce a 20% drop in FEV1 - measured in mg/ml and reported on log base 2 scale.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Peripheral Blood Mononuclear Cell ADRB2 Cell Surface Density","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1680","spread":null},{"groupId":"OG001","value":"1863","spread":null}]}]}]},{"type":"SECONDARY","title":"Beta-2 Adrenergic Receptor Agonist-induced cAMP Production","description":"Peripheral blood mononuclear cells cAMP concentrations measured using isoproterenol (ISO) as a beta-2 adrenergic receptor agonist, and using phosphate buffered saline (PBS) as a positive control. The outcome is expressed as the ratio of cAMP concentration using ISO relative to cAMP concentration using PBS.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Salivary Alpha Amylase Ratio (Post-Salmeterol / Pre-Salmeterol)","description":"Salivary Alpha Amylase (sAA) levels from saliva samples obtained through passive drooling, before and 1 hour after Salmeterol administration. The outcome is expressed as the ratio of the Post-Salmeterol to the Pre-Salmeterol sAA levels.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Asthma Control Test (ACT)","description":"Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Fractional Exhaled Nitrix Oxide","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":["headache","Acute nasopharyngitis","Acue Upper Respiratory Infection","Acute sinusitis","Nausea alone"]}}}